Liminatus PharmaLIMN +9.99%13 Current Ratio is 0.96 as of Mar. 2026, which is 405% above its 10-year median of 0.19. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Liminatus Pharma ranks worse than 85.21% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Liminatus Pharma's current ratio for the quarter that ended in Mar. 2026 was 0.96.
Liminatus Pharma has a current ratio of 0.96. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Liminatus Pharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Liminatus Pharma's Current Ratio or its related term are showing as below:
LIMN'
s Current Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.19 Max: 0.96
Current: 0.96
During the past 4 years, Liminatus Pharma's highest Current Ratio was 0.96. The lowest was 0.05. And the median was 0.19.
LIMN's Current Ratio is ranked worse than 85.21% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs LIMN: 0.96
Liminatus Pharma (NAS:LIMN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Liminatus Pharma Current Ratio Related Terms
Liminatus Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIMN vs XBIO, PCSA, SILO: Current Ratio Comparison
For the Biotechnology subindustry, Liminatus Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liminatus Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Liminatus Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liminatus Pharma (LIMN) has a Current Ratio of 0.96 as of Mar. 2026. This is 405% above median its historical median of 0.19. Over the past decade, Liminatus Pharma's Current Ratio has ranged from 0.05 to 0.96. According to the industry distribution chart, Liminatus Pharma ranks #1204 out of 1413 companies in the Biotechnology industry, placing it in the top 85.2%.
Is Liminatus Pharma's Current Ratio too high?
Liminatus Pharma's current Current Ratio of 0.96 is 405% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.96. The Biotechnology industry median Current Ratio is 3.89. Liminatus Pharma's value of 0.96 is 75.3% below this industry median. Based on the distribution chart, Liminatus Pharma ranks #1204 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Current Ratio compare to XBIO and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #1204 out of 1413 companies for Current Ratio. This places Liminatus Pharma in the lower half of its industry. The industry median Current Ratio is 3.89. Liminatus Pharma's value of 0.96 is 75.3% below this benchmark. Historically, Liminatus Pharma's own Current Ratio has ranged from 0.05 to 0.96 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 3.89, Liminatus Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liminatus Pharma's current Current Ratio of 0.96 is 75.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current Current Ratio is 0.96, which is 405% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Current Ratio of 0.96. The current Current Ratio is 0.96, which is 405% above median its 10-year median of 0.19 and 75.3% below the Biotechnology industry median of 3.89. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Current Ratio is 0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
